Yaron Goldman, MD
Pulmonary Disease · Worcester, MANPI 1649499823
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $749,809 of the $843,283 with a category attached, or 88.9%. 24 manufacturers reported payments, led by GSK at 38.3% of the total. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,144 payments — averaging $737.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$323K
- AstraZeneca$212K
- Sanofi$103K
- Boehringer Ingelheim$97K
- Regeneron Healthcare Solutions, Inc.$82K
- Verona Pharma, Inc.$13K
- plus $14K from 18 others
What the payments were for
- Consulting fees$24,9203%
- Speaking & faculty fees$749,80989%
- Travel & lodging$38,8255%
- Food & beverage$29,4223%
- Education$2900%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 366 | $323,155 |
| AstraZeneca | 341 | $211,506 |
| Sanofi | 108 | $102,825 |
| Boehringer Ingelheim | 171 | $96,918 |
| Regeneron Healthcare Solutions, Inc. | 92 | $81,797 |
| Verona Pharma, Inc. | 17 | $12,889 |
| Amgen | 15 | $9,342 |
| Viiv Healthcare Company | 2 | $3,496 |
| Actelion Pharmaceuticals US, Inc. | 9 | $545 |
| Inspire Medical Systems, Inc. | 2 | $333 |
| United Therapeutics Corporation | 4 | $91 |
| Merck | 3 | $67 |
| Insmed, Inc. | 2 | $61 |
| Novartis | 2 | $47 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
| Pulmonx Corporation | 1 | $27 |
| Mylan Specialty L.p. | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| ZOLL Respicardia, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Resmed Corp | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$843,283 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 653 | $529,314 |
| OpsumitMacitentan | 39 | $500,924 |
| AdempasRiociguat | 24 | $335,658 |
| OfevNintedanib Esylate | 22 | $288,734 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 24 | $257,546 |
| NucalaMepolizumab | 54 | $206,071 |
| Dupixent PenDupilumab | 48 | $179,551 |
| Fasenra PenBenralizumab | 29 | $161,796 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 212 | $155,891 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 290 | $143,987 |
| Breo ElliptaFluticasone/Vilanterol | 209 | $109,456 |
| Spiriva RespimatTiotropium Bromide | 51 | $39,389 |
| EliquisApixaban | 49 | $28,826 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 85 | $26,136 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $20,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $323,155 | $1,023,0041,308 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $545 | $500,92439 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $96,918 | $357,722115 claims |
| Grifols USA, LLCProlastin C | $23 | $257,54624 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $211,506 | $173,128262 claims |
| PfizerEliquis | $17 | $28,82649 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $11 | $3,85618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Worcester
- Fernando MartinezWorcester$375K
- Abdo KatayaWorcester$16K
- Sandeep SomalarajuWorcester$15K
- Kevin MartinWorcester$14K
- Sarah GrantBrookline$678K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
- Adam SmithBurlington$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.